ICAD Quote, Financials, Valuation and Earnings

Retractable Technologies has a net margin of -17.09% compared to icad's net margin of -126.59%. icad's return on equity of -17.16% beat Retractable Technologies's return on equity of -26.39%.

icad has a consensus price target of $3.75, signalling upside risk potential of 0.27%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that icad has higher upside potential than Retractable Technologies, analysts believe icad is more attractive than Retractable Technologies.

icad has a beta of 1.367, which suggesting that the stock is 36.745% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.357, suggesting its more volatile than the S&P 500 by 35.696%.

icad has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. icad pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

icad quarterly revenues are $4.9M, which are smaller than Retractable Technologies quarterly revenues of $8.3M. icad's net income of -$833K is higher than Retractable Technologies's net income of -$10.5M. Notably, icad's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for icad is 5.06x versus 0.60x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -17.09% compared to icad's net margin of -2201.34%. icad's return on equity of -17.16% beat VolitionRX's return on equity of --.

icad has a consensus price target of $3.75, signalling upside risk potential of 0.27%. On the other hand VolitionRX has an analysts' consensus of $2.94 which suggests that it could grow by 340.32%. Given that VolitionRX has higher upside potential than icad, analysts believe VolitionRX is more attractive than icad.

icad has a beta of 1.367, which suggesting that the stock is 36.745% more volatile than S&P 500. In comparison VolitionRX has a beta of 1.198, suggesting its more volatile than the S&P 500 by 19.798%.

icad has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. icad pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

icad quarterly revenues are $4.9M, which are larger than VolitionRX quarterly revenues of $246.4K. icad's net income of -$833K is higher than VolitionRX's net income of -$5.4M. Notably, icad's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for icad is 5.06x versus 46.02x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -17.09% compared to icad's net margin of -2828.67%. icad's return on equity of -17.16% beat Catheter Precision's return on equity of -137.84%.

icad has a consensus price target of $3.75, signalling upside risk potential of 0.27%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 727.82%. Given that Catheter Precision has higher upside potential than icad, analysts believe Catheter Precision is more attractive than icad.

icad has a beta of 1.367, which suggesting that the stock is 36.745% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.724, suggesting its less volatile than the S&P 500 by 172.434%.

icad has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. icad pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

icad quarterly revenues are $4.9M, which are larger than Catheter Precision quarterly revenues of $143K. icad's net income of -$833K is higher than Catheter Precision's net income of -$4M. Notably, icad's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for icad is 5.06x versus 2.77x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -17.09% compared to icad's net margin of 0.18%. icad's return on equity of -17.16% beat Xtant Medical Holdings's return on equity of -26.62%.

icad has a consensus price target of $3.75, signalling upside risk potential of 0.27%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 167.18%. Given that Xtant Medical Holdings has higher upside potential than icad, analysts believe Xtant Medical Holdings is more attractive than icad.

icad has a beta of 1.367, which suggesting that the stock is 36.745% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.918%.

icad has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. icad pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

icad quarterly revenues are $4.9M, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. icad's net income of -$833K is lower than Xtant Medical Holdings's net income of $58K. Notably, icad's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for icad is 5.06x versus 0.73x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.